Literature DB >> 26169412

Multidrug Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal Resistance in Candida parapsilosis.

Elizabeth L Berkow1, Kayihura Manigaba1, Josie E Parker2, Katherine S Barker1, Stephen L Kelly2, P David Rogers3.   

Abstract

While much is known concerning azole resistance in Candida albicans, considerably less is understood about Candida parapsilosis, an emerging species of Candida with clinical relevance. We conducted a comprehensive analysis of azole resistance in a collection of resistant C. parapsilosis clinical isolates in order to determine which genes might play a role in this process within this species. We examined the relative expression of the putative drug transporter genes CDR1 and MDR1 and that of ERG11. In isolates overexpressing these genes, we sequenced the genes encoding their presumed transcriptional regulators, TAC1, MRR1, and UPC2, respectively. We also sequenced the sterol biosynthesis genes ERG3 and ERG11 in these isolates to find mutations that might contribute to this phenotype in this Candida species. Our findings demonstrate that the putative drug transporters Cdr1 and Mdr1 contribute directly to azole resistance and suggest that their overexpression is due to activating mutations in the genes encoding their transcriptional regulators. We also observed that the Y132F substitution in ERG11 is the only substitution occurring exclusively among azole-resistant isolates, and we correlated this with specific changes in sterol biosynthesis. Finally, sterol analysis of these isolates suggests that other changes in sterol biosynthesis may contribute to azole resistance in C. parapsilosis.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26169412      PMCID: PMC4576097          DOI: 10.1128/AAC.01358-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals.

Authors:  P F Watson; M E Rose; S W Ellis; H England; S L Kelly
Journal:  Biochem Biophys Res Commun       Date:  1989-11-15       Impact factor: 3.575

2.  Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).

Authors:  Andrew G S Warrilow; Claire M Martel; Josie E Parker; Nadja Melo; David C Lamb; W David Nes; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

Review 3.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

4.  A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans.

Authors:  Alix Coste; Vincent Turner; Françoise Ischer; Joachim Morschhäuser; Anja Forche; Anna Selmecki; Judith Berman; Jacques Bille; Dominique Sanglard
Journal:  Genetics       Date:  2006-02-01       Impact factor: 4.562

5.  Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation.

Authors:  S L Kelly; D C Lamb; D E Kelly; N J Manning; J Loeffler; H Hebart; U Schumacher; H Einsele
Journal:  FEBS Lett       Date:  1997-01-02       Impact factor: 4.124

6.  Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes.

Authors:  Sarah MacPherson; Bassel Akache; Sandra Weber; Xavier De Deken; Martine Raymond; Bernard Turcotte
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 7.  Epidemiology of invasive mycoses in North America.

Authors:  Michael A Pfaller; Daniel J Diekema
Journal:  Crit Rev Microbiol       Date:  2010       Impact factor: 7.624

8.  Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans.

Authors:  Stephanie A Flowers; Katherine S Barker; Elizabeth L Berkow; Geoffrey Toner; Sean G Chadwick; Scott E Gygax; Joachim Morschhäuser; P David Rogers
Journal:  Eukaryot Cell       Date:  2012-08-24

9.  Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol.

Authors:  S L Kelly; D C Lamb; A J Corran; B C Baldwin; D E Kelly
Journal:  Biochem Biophys Res Commun       Date:  1995-02-27       Impact factor: 3.575

10.  The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans.

Authors:  Joachim Morschhäuser; Katherine S Barker; Teresa T Liu; Julia BlaB-Warmuth; Ramin Homayouni; P David Rogers
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

View more
  29 in total

1.  Regulatory Role of ERG3 and Efg1 in Azoles-Resistant Strains of Candida albicans Isolated from Patients Diagnosed with Vulvovaginal Candidiasis.

Authors:  Wenli Feng; Jing Yang; Zhiqin Xi; Ying Ji; Xin Zhu; Lu Yang; Yan Ma
Journal:  Indian J Microbiol       Date:  2019-11-02       Impact factor: 2.461

2.  Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Authors:  Jeffrey M Rybak; C Michael Dickens; Josie E Parker; Kelly E Caudle; Kayihura Manigaba; Sarah G Whaley; Andrew T Nishimoto; Arturo Luna-Tapia; Sujoy Roy; Qing Zhang; Katherine S Barker; Glen E Palmer; Thomas R Sutter; Ramin Homayouni; Nathan P Wiederhold; Steven L Kelly; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Whole-Genome and Targeted-Amplicon Sequencing of Fluconazole-Susceptible and -Resistant Candida parapsilosis Isolates from Kuwait Reveals a Previously Undescribed N1132D Polymorphism in CDR1.

Authors:  Mohammad Asadzadeh; Mohammed Dashti; Suhail Ahmad; Wadha Alfouzan; Abbas Alameer
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 4.  Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard.

Authors:  Shawn R Lockhart; Mahmoud A Ghannoum; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2017-02-15       Impact factor: 5.948

Review 5.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

6.  A CTG Clade Candida Yeast Genetically Engineered for the Genotype-Phenotype Characterization of Azole Antifungal Resistance in Human-Pathogenic Yeasts.

Authors:  Isabelle Accoceberry; Amandine Rougeron; Nicolas Biteau; Pauline Chevrel; Valérie Fitton-Ouhabi; Thierry Noël
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  General hospital outbreak of invasive candidiasis due to azole-resistant Candida parapsilosis associated with an Erg11 Y132F mutation.

Authors:  Dora E Corzo-Leon; Mark Peacock; Patricia Rodriguez-Zulueta; Grace J Salazar-Tamayo; Donna M MacCallum
Journal:  Med Mycol       Date:  2021-07-06       Impact factor: 4.076

8.  Candida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance.

Authors:  Laura A Doorley; Jeffrey M Rybak; Elizabeth L Berkow; Qing Zhang; Joachim Morschhäuser; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2022-06-14       Impact factor: 5.938

9.  First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant Candida parapsilosis Isolates Harboring Y132F and/or Y132F+K143R in Turkey.

Authors:  Amir Arastehfar; Farnaz Daneshnia; Suleyha Hilmioğlu-Polat; Wenjie Fang; Melike Yaşar; Furkan Polat; Dilek Yeşim Metin; Petra Rigole; Tom Coenye; Macit Ilkit; Weihua Pan; Wanqing Liao; Ferry Hagen; Markus Kostrzewa; David S Perlin; Cornelia Lass-Flörl; Teun Boekhout
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

10.  The efflux pump inhibitor tetrandrine exhibits synergism with fluconazole or voriconazole against Candida parapsilosis.

Authors:  Ya-Jing Zhao; Wei-Da Liu; Yong-Nian Shen; Dong-Mei Li; Kun-Ju Zhu; Hong Zhang
Journal:  Mol Biol Rep       Date:  2019-08-12       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.